Last reviewed · How we verify

NCT03170011

Biodex Sit2Stand for Individuals With Cardiac Disease

Withdrawn NA Last updated 19 September 2019
What this trial tests

NA trial testing Exercise using the Biodex Sit2Stand Trainer in Coronary Artery Disease. Withdrawn.

Timeline
1 June 2017
Primary endpoint
15 September 2017
15 September 2017

Quick facts

Lead sponsorSt. Ambrose University
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Start date1 June 2017
Primary completion15 September 2017
Estimated completion15 September 2017

Drugs / interventions tested

Conditions studied

Sponsor

St. Ambrose University

Who can join

Adults 18 to 100, any sex, with Coronary Artery Disease or Frail Elderly Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with cardiac disease have been shown to have deficits in activities such as standing up from a chair. The Biodex Sit2Stand Trainer is a new device meant to improve sit to stand performance by providing a lifting force through the seat to help the individual stand. The amount of lift can be graded to help improve leg strength, endurance, and function over time. The device has the potential to be a form of training for those in cardiac rehabilitation who have limitations in standing from a chair.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

Other St. Ambrose University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03170011.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing